Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
TriSalus Life Sciences, Inc. - Common Stock
(NQ:
TLSI
)
5.695
-0.055 (-0.96%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
261,440
Open
5.480
Bid (Size)
2.280 (2)
Ask (Size)
6.020 (15)
Prev. Close
5.750
Today's Range
5.450 - 5.750
52wk Range
3.320 - 10.44
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
TLSI stock results show that TriSalus Life Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
TriSalus Reports Q2 2024 Financial Results and Business Update
August 15, 2024
From
TriSalus Life Sciences
Via
Business Wire
Performance
YTD
-30.97%
-30.97%
1 Month
-0.61%
-0.61%
3 Month
-43.89%
-43.89%
6 Month
-38.43%
-38.43%
1 Year
-36.51%
-36.51%
More News
Read More
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
August 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
July 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
June 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
June 03, 2024
From
TriSalus Life Sciences
Via
Business Wire
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 24, 2024
Via
Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
May 24, 2024
Via
Benzinga
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
May 24, 2024
From
TriSalus Life Sciences
Via
Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024
May 15, 2024
Via
InvestorPlace
TriSalus Reports Q1 2024 Financial Results and Business Update
May 15, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
May 07, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
May 06, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
April 30, 2024
From
TriSalus Life Sciences
Via
Business Wire
TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023
April 01, 2024
Via
InvestorPlace
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
April 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
Earnings Scheduled For April 1, 2024
April 01, 2024
Via
Benzinga
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
March 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
March 21, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
March 07, 2024
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
February 29, 2024
From
TriSalus Life Sciences
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
December 14, 2023
Via
Benzinga
TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From
TriSalus Life Sciences Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.